Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study
Acta Haematologica Oncologica Turcica, cilt.58, sa.1, ss.40-45, 2025 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 58 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.4274/ahot.galenos.2025.2025-1-1
- Dergi Adı: Acta Haematologica Oncologica Turcica
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.40-45
- Anahtar Kelimeler: Colorectal cancer, metastasectomy, prognosis, survival outcomes, treatment planning
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Metastasectomy is a significant intervention in metastatic colorectal cancer (mCRC) management. This study uniquely evaluates metastasectomy outcomes by metastatic site and underscores the critical role of R0 resection, offering real-world insights into tailored treatment strategies for mCRC. Our findings align with existing literature, particularly regarding the survival benefits of lung metastasectomy and the importance of achieving complete tumor resection Methods: This retrospective cohort study included 73 patients with colon cancer who underwent metastasectomy between January 2014 and June 2023. Demographic, clinical, and treatment data were analyzed. Survival outcomes were assessed using Kaplan-Meier analysis. Results: The median overall survival (OS) for the entire cohort was 40.4 months. Patients undergoing lung metastasectomy demonstrated the longest median survival (53.6 months), followed by liver (41.7 months) and intraabdominal metastasectomy (35.5 months). R0 resections were associated with improved OS (median: 69.6 months), while non-R0 resections had poorer outcomes. Synchronous metastases were linked to shorter OS than metachronous metastases, although the difference was not statistically significant (p=0.09). Conclusion: Metastasectomy significantly improves survival outcomes in mCRC, with lung metastasectomy showing the most favorable results. Achieving R0 resection is crucial for optimizing survival benefits. These findings underscore the importance of individualized treatment planning in patients undergoing metastasectomy.